Basic Information
| LncRNA/CircRNA Name | lncRNA-ATB |
| Synonyms | LOC109207222 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, other |
| Sample | HCC serum sample |
| Expression Pattern | up-regulated |
| Function Description | Both circulating exosomal miRNA-21 and lncRNA-ATB were related to TNM stage and other prognostic factors, including the T stage and portal vein thrombosis. Multivariate analysis using the Cox regression test identified that both higher miRNA-21 and higher lncRNA-ATB were independent predictors of mortality and disease progression, along with larger tumor size and higher C-reactive protein (all p < 0.05). The overall survival and progression-free survival were significantly lower in patients with higher circulating levels of exosomal miRNA-21 (??.09) and lncRNA-ATB (??.0016) (log-rank test: p < 0.05). |
| Pubmed ID | 30338850 |
| Year | 2019 |
| Title | Circulating Exosomal Noncoding RNAs as Prognostic Biomarkers in Human Hepatocellular Carcinoma |
External Links
| Links for lncRNA-ATB | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |